Claims
- 1. A taxane derivative having the formula whereinX1 is —OX6, —SX7, or —NX8X9; X2 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; X3 is alkyl; X4 is hydrogen; X5 is —COX10, —COOX10, —COSX10, —CONX8X10, or —SO2X11; X6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxy protecting group; X7 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group; X8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl; X9 is an amino protecting group; X10 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl alkynyl, aryl or heteroaryl; X11 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, —OX10, or —NX8X14; X14 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; R1 is hydrogen, hydroxy, protected hydroxy or together with R14 forms a carbonate; R2 is hydrogen, hydroxy, —OCOR31 together with R2a forms an oxo; R2a is hydrogen or taken together with R2 forms an oxo or; R4 is hydrogen, together with R4a forms an oxo, oxirane or methylene, or together with R5a and the carbon atoms to which they are attached form an oxetane ring; R4a is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyano, hydroxy, —OCOR30, or together with R4 forms an oxo, oxirane or methylene; R5 is hydrogen or together with R5a forms an oxo, R5a is hydrogen, hydroxy, protected hydroxy, acyloxy, together with R5 forms an oxo, or together with R4 and the carbon atoms to which they are attached form an oxetane ring; R6 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R6a forms an oxo; R6a is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R6 forms an oxo; R7 is hydrogen or together with R7a forms an oxo, R7a is hydrogen, halogen, protected hydroxy, —OR28, or together with R7 forms an oxo; R9 is hydrogen or together with R9a forms an oxo, R9a is hydrogen, hydroxy, protected hydroxy, acyloxy, or together with R9 forms an oxo; R10 is hydrogen or together with R10a forms an oxo, R10a is hydrogen, —OCOR29, hydroxy, or protected hydroxy, or together with R10 forms an oxo; R14 is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy, protected hydroxy or together with R1 forms a carbonate; R14a is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl; R28 is hydrogen, acyl, or hydroxy protecting group; R29, R30, and R31 are independently hydrogen, alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl; and the taxane has a structure which differs from that of taxol or docetaxel with respect to the C13 side chain and at least one other substituent.
- 2. The taxane derivative of claim 1 wherein X3 is cyclohexyl, cyclopropyl, cyclopentyl, cyclobutyl, propyl, or butyl.
- 3. The taxane derivative of claim 2 wherein X5 is —COX10 and X10 is furyl or thienyl.
- 4. The taxane derivative of claim 2 wherein X5 is —COOX10, and X10 is alkyl R9 is hydrogen and R9a is hydroxy.
- 5. The taxane derivative of claim 2 whereinR10 is hydrogen or together with R10a forms an oxo, R10a is hydrogen, hydroxy, protected hydroxy or —OCOR29, or together with R10 forms an oxo; R9 is hydrogen or together with R9a forms an oxo; R9a is hydrogen, acyloxy or together with R9 forms an oxo; R7 is hydrogen, R7a is hydrogen, halogen or —OR28; R5 is hydrogen; R5a together with R4 and the carbon atoms to which they are attached form an oxetane ring; R4a is hydrogen, hydroxy, acetoxy or —OCOR30, R2 is hydrogen, hydroxy, —OCOR31 or taken together with R2a forms an oxo; R2a is hydrogen or taken together with R2 forms an oxo; R1 is hydrogen, hydroxy, protected hydroxy; R28 is hydrogen, acyl, or hydroxy protecting group; and R29, R30, and R31 are independently hydrogen, alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl.
- 6. A pharmaceutical composition which contains the taxane derivative of claim 1 and one or more pharmacologically acceptable, inert physiologically active diluents or adjuvants.
- 7. The taxane of claim 1 wherein X1 is —OH, X2 is hydrogen, X4 is hydrogen, X5 is —COX10 or —COOX10 and X10 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl and the taxane has the 2′R,3′S configuration.
- 8. The taxane of claim 1 wherein X1 is —OH; X2 is hydrogen; X3 is substituted or unsubstituted isopropyl, cyclopropyl, n-butyl, t-butyl, cyclobutyl, or cyclohexyl; X4 is hydrogen; X5 is —COX10 or —COOX10 and X10 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl; and the taxane has the 2′R,3′S configuration.
- 9. The taxane of claim 1 wherein R14 is hydroxy.
- 10. A pharmaceutical composition which contains the taxane derivative of claim 2 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.
- 11. A pharmaceutical composition which contains the taxane derivative of claim 7 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.
- 12. A pharmaceutical composition which contains the taxane derivative of claim 8 and one or more pharmacologically acceptable, inert or physiologically active diluents or adjuvants.
REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of U.S. Ser. No. 09/685,621, filed Oct. 10, 2000, now abandoned which is a continuation application of U.S. Ser. No. 08/462,125, filed Jun. 5, 1995, now U.S. Pat. No. 6,335,362, which is a continuation application of U.S. Ser. No. 08/094,756 filed Jul. 20, 1993, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 08/034,247 filed Mar. 22, 1993, now U.S. Pat. No. 5,430,160, which is a continuation-in-part of U.S. Ser. No. 07/949,107, filed Sep. 22, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/863,849, filed Apr. 6, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/862,955, filed Apr. 3, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned. Said Ser. No. 08/462,125, filed Jun. 5, 1995 is also a continuation-in-part application of U.S. Ser. No. 07/976,331, filed Nov. 13, 1992, now U.S. Pat. No. 5,284,565, which is a continuation-in-part application of U.S. Ser. No. 07/949,107, filed Sep. 22, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/863,849, filed Apr. 6, 1992, now abandoned, which is a continuation-in-part application of U.S. Ser. No. 07/862,955, filed Apr. 3, 1992, now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/763,805, filed Sep. 23, 1991, now abandoned.
US Referenced Citations (22)
Foreign Referenced Citations (10)
Number |
Date |
Country |
0 400 971 |
May 1990 |
EP |
0 568 203 |
Mar 1993 |
EP |
0 558 959 |
Aug 1993 |
EP |
0 582 469 |
Feb 1994 |
EP |
0 590 267 |
Apr 1994 |
EP |
0 712 854 |
May 1996 |
EP |
0 428 376 |
Oct 1996 |
EP |
0 577 082 |
Oct 1996 |
EP |
0 605 638 |
Jan 1999 |
EP |
0 605 637 |
Mar 1999 |
EP |
Continuations (3)
|
Number |
Date |
Country |
Parent |
09/685621 |
Oct 2000 |
US |
Child |
10/134762 |
|
US |
Parent |
08/462125 |
Jun 1995 |
US |
Child |
07/976331 |
|
US |
Parent |
08/094756 |
Jul 1993 |
US |
Child |
08/462125 |
|
US |
Continuation in Parts (10)
|
Number |
Date |
Country |
Parent |
07/976331 |
Nov 1992 |
US |
Child |
09/685621 |
|
US |
Parent |
08/034247 |
Mar 2001 |
US |
Child |
08/094756 |
|
US |
Parent |
07/949107 |
Sep 1993 |
US |
Child |
08/034247 |
|
US |
Parent |
07/863849 |
Apr 1992 |
US |
Child |
07/949107 |
|
US |
Parent |
07/862955 |
Apr 1992 |
US |
Child |
07/863849 |
|
US |
Parent |
07/763805 |
Sep 1991 |
US |
Child |
07/862955 |
|
US |
Parent |
07/949107 |
Sep 1992 |
US |
Child |
08/462125 |
Jun 1995 |
US |
Parent |
07/863849 |
Apr 1992 |
US |
Child |
07/949107 |
|
US |
Parent |
07/862955 |
Apr 1992 |
US |
Child |
07/863849 |
|
US |
Parent |
07/763805 |
Sep 1991 |
US |
Child |
07/862955 |
|
US |